Elucidation of an inhibitory mechanism of septic immunothrombosis by novel plasma factor:HRG
| Project/Area Number |
17K15580
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
Wake Hidenori 岡山大学, 医歯薬学総合研究科, 講師 (60570520)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | HRG / 敗血症 / 免疫血栓形成 / 血管内皮障害 / 活性酸素 / 免疫血栓 / 2価鉄イオン / Immunothrombosis / In vivoイメージング / Ｉｍｍｕｎｏｔｈｒｏｍｂｏｓｉｓ / ＨＲＧ |
|---|
| Outline of Final Research Achievements |
Histidine-rich glycoprotein (HRG) is a plasma glycoprotein. Plasma HRG levels decreased in septic condition and HRG supplementary therapy improves lethality in sepsis. We elucidated that HRG modulates a dysregulated immunothrombus formation by suppression of aggregation of neutrophils, platelets and erythrocytes, and adhesion of these cells to endothelial cells because HRG detoxifies immunothrombosis-inducing factors (LPS, zinc, reactive oxygen species, polyphosphate). Additionally, we were successful in intravital visualization of these phenomena.
|
| Academic Significance and Societal Importance of the Research Achievements |
HRGが敗血症病態を改善するより詳細な作用機序を明らかにすることにより、正しい敗血症の理解に寄与するとともに、新たな視点からの敗血症治療薬の開発に貢献する。また、今回構築した生体内イメージングの手法は、より正確な生体内血球細胞動態や血管状態を把握する上で役立ち、敗血症のみならず、他の病態への応用も可能である。
|
Report
(4 results)
Research Products
(21 results)
